PARP-1 inhibitor has been approved for clinical treatments for several tumors, such as ovarian cancers (Lin and Kraus, 2017), microsatellite unstable cancers (Chan et al., 2019) and pancreatic cancers (Tuli et al., 2019), with satisfactory clinical effects and safety. Here, PARP1 is linked to cancer.